FDA Warns On Possible Heart, Diabetes Risk With Prostate Cancer Drugs Including Abbott Laboratories’ Lupron, AstraZeneca PLC’s Zoladex, Sanofi-Aventis (France)'s Eligard, and Pfizer Inc.'s Synarel

Wall Street Journal -- WASHINGTON (Dow Jones)--New warnings about the potential risk of cardiovascular problems and diabetes will be added to the labels of hormone-therapy drugs that are used to treat prostate cancer, the Food and Drug Administration said Wednesday.